WEBULL
WebtradeDownload

Veeva Systems (VEEV) Could Be 21% Undervalued After IQVIA Expanded Its Partnership

Simply Wall St · 1d ago

Veeva Systems (VEEV) is back in focus after global contract research group IQVIA chose multiple Veeva clinical applications as enterprise standards for all its development studies, expanding an earlier partnership.

Recent news around IQVIA deepening its use of Veeva Systems, alongside product updates in AI driven clinical and quality tools, has arrived during a strong run in the shares. The 90 day share price return is 55.74% and the year to date share price gain is 37.42%, even though the 5 year total shareholder return is slightly negative at 5.52% and the 1 year total shareholder return of 4.86% trails the shorter term momentum.

Spot other fast-moving health and AI plays by scanning our curated list of 33 healthcare AI stocks, which, like Veeva Systems, tie software and data directly to clinical workflows.

After a 56% jump in 90 days, Veeva Systems now offers a clear fork in the road for investors. Should they lean into the momentum, or wait for the valuation math to offer a cleaner entry point?

Most Popular Narrative: 21% Undervalued

Against the last close at $301.63, the most followed narrative on Veeva Systems pegs fair value higher at $383.14. This frames the current rally as momentum inside an already undervalued story rather than late-stage euphoria.

The moat is not software. It is the cost of being wrong.

Most enterprise software can be replaced with enough time, money, and executive determination.

See why 52 investors see Veeva Systems as 21% undervalued.

Result: Fair Value of $383.14 (UNDERVALUED)

Still, Veeva Systems faces real pressure points if large pharma consolidations slow software decisions or if Falcon’s AI rollout fails to translate into durable, paid adoption.

Find out about the key risks to this Veeva Systems narrative.

Another View on Veeva Systems’ Valuation

The user narrative leans on a P/E based fair value near $320, yet Veeva Systems currently trades on a 48.1x P/E while our fair ratio sits at 32.2x. That is richer than both the global Healthcare Services average of 28.6x and the peer group on 47.8x. For investors, does paying this kind of premium widen the risk of a painful pullback if expectations cool?

See what the numbers say about this price in our breakdown, starting with See what the numbers say about this price — find out in our valuation breakdown..

NYSE:VEEV P/E Ratio as at Oct 2026
NYSE:VEEV P/E Ratio as at Oct 2026

Next Steps

Mixed messages on Veeva Systems so far. Momentum looks strong and the valuation debate is live, so move quickly, review the underlying metrics, and weigh both the 3 key rewards and 1 important warning sign.

Looking for more ideas beyond Veeva Systems?

Use the same disciplined lens you brought to Veeva Systems to hunt for fresh opportunities, before the next wave of money moves on without you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.